Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis

Recruiting Phase 3 Interventional Study
ICU Yeast Intra-abdominal Infection
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
448 (estimated)
Sponsor
Centre Hospitalier Universitaire, Amiens · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The incidence of intra-abdominal candidiasis is increasing, and it is now the leading indication for antifungal therapy, ahead of candidemia. Prospective randomized trials of antifungal therapy have almost exclusively concerned patients with candidemia and did not include patients with intra-abdominal infections. The aim of this study is to demonstrate that caspofungin antifungal therapy for intra…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * Covered by national health insurance * Admitted to ICU after surgery for intra-abdominal infection : * With suspected intra-abdominal candidiasis defined by a Peritonitis score ≥ 3(1) * Or with documented intra-abdominal candidiasis defined by positiv…
Contacts

Hervé Dupont, PD

33 322 087 979

dupont.herve@chu-amiens.fr

CONTACT

Hervé Dupont

33 322 087 979

dupont.herve@chu-amiens.fr

CONTACT